Studies suggest that patients with sarcomeric mutations (MYH7 and MYBPC3) can benefit from its use early in the disease. The described rationale accounts for inhibiting transforming growth factor-beta (TGF-b), a cytokine involved in myocardial hypertrophy and fibrosis. The gene discussed is MYH7; the disease is cardiac hypertrophy.